Former Quad President requests debarment hearing through a Dec. 4 letter to FDA by the Washington, D.C. law firm Zuckerman, Spaeder, Goldstein, Taylor & Kolker. The letter requests a hearing to contest FDA's Nov. 5 proposal to debar Shah permanently from "providing services in any capacity to a [company] that has an approved or pending drug product application" ("The Pink Sheet" Dec. 14, In Brief). The law firm argues that Shah's "conduct does not fall within the conduct encompassed" by the section on mandatory debarment of individuals but instead falls within the section on permissive debarment of individuals. The firm also said that the debarment provisions "do not apply to convictions that predate enactment of the statute, as in the case with Dr. Shah's conviction".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth